Adult Onset of BRAF(V600E)-Mutated Langerhans Cell Histiocytosis with Cutaneous Involvement Successfully Diagnosed by Immunohistochemical Staining

被引：2
作者：
Tono, Hisayuki [1 ]
Fujimura, Taku [1 ]
Kakizaki, Aya [1 ]
Furudate, Sadanori [1 ]
Ishibashi, Masaya [1 ]
Aiba, Setsuya [1 ]
机构：
[1] Tohoku Univ, Grad Sch Med, Dept Dermatol, Sendai, Miyagi, Japan
来源：
CASE REPORTS IN DERMATOLOGY | 2015年 / 7卷 / 03期
关键词：
Adult onset of Langerhans cell histiocytosis; BRAF(V600E); Clinical type; Chemotherapy;
D O I：
10.1159/000440643
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Langerhans cell histiocytosis (LCH) is characterized by the clonal proliferation of Langerhans cells; it is categorized as a single-system disease with single or multifocal lesions, and as a multi-system disease with or without the risk of organ involvement. Although the skin is not categorized as a risk organ, the precise diagnosis of skin lesions is necessary to determine the protocol for the treatment of LCH. In this report, we describe a 28-year-old Japanese man with adult onset of BRAF(V600E)-mutated LCH with cutaneous involvement successfully diagnosed by immunohistochemical staining. Our report suggests that immunohistochemical staining for the BRAF(V600E) gene could be a diagnostic tool to determine the clinical type of LCH. (C) 2015 The Author(s) Published by S. Karger AG, Basel
引用
收藏
页码：237 / 240
页数：4
相关论文
共 9 条
  • [1] V600E BRAF versus Non-V600E BRAF Mutated Lung Adenocarcinomas: Cytomorphology, Histology, Coexistence of Other Driver Mutations and Patient Characteristics
    Salimian, Kevan J.
    Fazeli, Roghayeh
    Zheng, Gang
    Ettinger, David
    Maleki, Zahra
    ACTA CYTOLOGICA, 2018, 62 (02) : 79 - 84
  • [2] Clinical Manifestations of Adult Langerhans Cell Histiocytosis with Multisystem Involvement Successfully Treated Using Chemotherapy
    Lin Nai-Yu
    Tang Xu-Hua
    Han Jian-De
    国际皮肤性病学杂志（英文）, 2021, 04 (02) : 122 - 124
  • [3] Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors
    Nasca, Vincenzo
    Zhao, Joseph
    Ros, Javier
    Lonardi, Sara
    Zwart, Koen
    Cohen, Romain
    Fakih, Marwan
    Jayachandran, Priya
    Roodhart, Jeanine M. L.
    Derksen, Jeroen
    Intini, Rossana
    Bergamo, Francesca
    Mazzoli, Giacomo
    Ghelardi, Filippo
    Ligero, Marta
    Jonnagaddala, Jitendra
    Hawkins, Nicholas
    Ward, Robyn L.
    Wankhede, Durgesh
    Brenner, Hermann
    Hoffmeister, Michael
    Vitellaro, Marco
    Salvatore, Lisa
    Gallois, Claire
    Laurent-Puig, Pierre
    Cremolini, Chiara
    Overman, Michael J.
    Taieb, Julien
    Tougeron, David
    Andre, Thierry
    Kather, Jakob Nikolas
    Sundar, Raghav
    Carmona, Javier
    Elez, Elena
    Koopman, Miriam
    Pietrantonio, Filippo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (02)
  • [4] Adding to the targeted therapy toolbox: BRAF and MEK inhibition in the treatment of BRAF V600E metastatic non-small cell lung cancer
    Myall, Nathaniel J.
    Wakelee, Heather A.
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S1233 - S1240
  • [5] BRAF plus EGFR plus /- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer
    Ambrosini, Margherita
    Tougeron, David
    Modest, Dominik
    Guimbaud, Rosine
    Kopetz, Scott
    Decraecker, Marie
    Kim, Stefano
    Coutzac, Clelia
    Perkins, Geraldine
    Alouani, Emily
    Marmorino, Federica
    Pernot, Simon
    Sinicrope, Frank A.
    Elez, Elena
    Parent, Pauline
    Cremolini, Chiara
    Pietrantonio, Filippo
    Lonardi, Sara
    Gallois, Claire
    Taieb, Julien
    EUROPEAN JOURNAL OF CANCER, 2024, 210
  • [6] Dabrafenib and trametinib therapy in an elderly patient with non-small cell lung cancer harboring the BRAF V600E mutation
    Dotsu, Yosuke
    Fukuda, Minoru
    Honda, Noritaka
    Gyotoku, Hiroshi
    Kohno, Yoshihisa
    Suyama, Takayuki
    Umeyama, Yasuhiro
    Taniguchi, Hirokazu
    Takemoto, Shinnosuke
    Yamaguchi, Hiroyuki
    Miyazaki, Taiga
    Sakamoto, Noriho
    Obase, Yasushi
    Ikeda, Hiroaki
    Ashizawa, Kazuto
    Mukae, Hiroshi
    THORACIC CANCER, 2021, 12 (02) : 272 - 276
  • [7] Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma
    Khalili, Jahan S.
    Liu, Shujuan
    Rodriguez-Cruz, Tania G.
    Whittington, Mayra
    Wardell, Seth
    Liu, Chengwen
    Zhang, Minying
    Cooper, Zachary A.
    Frederick, Dennie T.
    Li, Yufeng
    Zhang, Min
    Joseph, Richard W.
    Bernatchez, Chantale
    Ekmekcioglu, Suhendan
    Grimm, Elizabeth
    Radvanyi, Laszlo G.
    Davis, Richard E.
    Davies, Michael A.
    Wargo, Jennifer A.
    Hwu, Patrick
    Lizee, Gregory
    CLINICAL CANCER RESEARCH, 2012, 18 (19) : 5329 - 5340
  • [8] Dual BRAF/MEK therapy in BRAF V600E-mutated primary brain tumors: a case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity
    Bernstein, Aaron
    Mrowczynski, Oliver D.
    Greene, Amrit
    Ryan, Sandra
    Chung, Catherine
    Zacharia, Brad E.
    Glantz, Michael
    JOURNAL OF NEUROSURGERY, 2020, 133 (06) : 1704 - 1709
  • [9] Investigating therapeutic efficacy of dacarbazine and temozolomide, alone and in combination with BRAF(V600E) siRNA in A375 human melanoma cell line
    Tabandeh, Fatemeh
    Tehrani, Rana Moradian
    Sharifi, Mohammadreza
    Toopchi, Elmira
    IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2025, 28 (06) : 772 - 783
1